Product details
Background：
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin . Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia.
• Gene therapy for Alzheimer's disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation., PMID:32803224
• Hypoxia/ischemia impairs CD33 (Siglec-3)/TREM2 signaling: Potential role in Alzheimer's pathogenesis., PMID:34530055
• Reporter cell assay for human CD33 validated by specific antibodies and human iPSC-derived microglia., PMID:34188106
• CD33 isoforms in microglia and Alzheimer's disease: Friend and foe., PMID:35940942
• Siglecs in Brain Function and Neurological Disorders., PMID:31546700
• SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection., PMID:34060491
• Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab-Auristatin Conjugate with a Wide Therapeutic Window., PMID:38561023
• CD33 as a leukocyte-associated marker expressed on human spermatozoa., PMID:37081561
• Human brain sialoglycan ligand for CD33, a microglial inhibitory Siglec implicated in Alzheimer's disease., PMID:35452678
• Deletion of Alzheimer's disease-associated CD33 results in an inflammatory human microglia phenotype., PMID:33539598
